Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RC 108

Next Previous
Drug Profile

RC 108

Alternative Names: RC-108

Latest Information Update: 06 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator RemeGen
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Liver cancer; Non-small cell lung cancer
  • No development reported Renal cell carcinoma; Solid tumours

Most Recent Events

  • 17 Apr 2026 Pharmacodynamics data from a preclinical trial in Non-small cell lung cancer presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)
  • 31 Dec 2025 RemeGen Co completes a phase I trial in Solid tumours (Late-stage disease, Metastatic disease) in China (Parenteral) (NCT04617314)
  • 31 Dec 2025 RemeGen completes a phase-II trial in Gastrointestinal cancer, Colorectal cancer, Gastric cancer and Liver cancer (Late-stage disease, Metastatic disease) in China (NCT05628857)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top